Reta Stock News

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (Reata or the Company) (NASDAQ: RETA) in the United States District Court for the Eastern District of Texas on behalf of all persons and entities who purchased or otherwise acquired Reata securities between November 9, 2020 and December 8, 2021, both dates inclusive (the Class Period). Investors have until February 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $RETA #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors

(PR-inside.com) BOSTON, MA / ACCESSWIRE / December 21, 2021 / Block & Leviton announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (NASDAQ:RETA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/reta. What is this all about? On November 9, 2021, Reata announced that its Phase 3 CARDINAL study of bardoxolone in patients with chronic kidney disease caused by Alport syndrome "met its primary and key secondary endpoints at the end of Year 2," ..

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Reata Pharmaceuticals, Inc. (

At least one of the three could be in store for better news in the future.

Emerald Mutual Fund Advisers Trust raised its holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 11.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 280,816 shares of the companys stock after buying an additional 28,340 shares during the period. Emerald Mutual Fund Advisers Trust []

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) SVB Leerink boosted their FY2021 earnings per share (EPS) estimates for Reata Pharmaceuticals in a research report issued to clients and investors on Thursday, December 9th. SVB Leerink analyst J. Schwartz now expects that the company will post earnings per share of ($8.06) for the year, up from their previous [] The post Reata Pharmaceuticals, Inc. to Post FY2021 Earnings of ($8.06) Per Share, SVB Leerink Forecasts (NASDAQ:RETA) appeared first on ETF Daily News .

Robert W. Baird cut shares of Reata Pharmaceuticals (NASDAQ:RETA) from an outperform rating to a neutral rating in a research note issued to investors on Thursday, PriceTargets.com reports. They currently have $37.00 price target on the stock, down from their previous price target of $110.00. A number of other equities research analysts have also recently []

Reata Pharmaceuticals (NASDAQ:RETA) was downgraded by research analysts at The Goldman Sachs Group from a buy rating to a neutral rating in a research note issued to investors on Thursday, The Fly reports. They presently have a $39.00 price objective on the stock. The Goldman Sachs Groups price target would suggest a potential upside of []

LOS ANGELES--(BUSINESS WIRE)---- $RETA #investors--The Law Offices of Frank R. Cruz Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

The shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) have received a $68 price target from Cantor Fitzgerald. These are the details.

SVB Leerink reissued their market perform rating on shares of Reata Pharmaceuticals (NASDAQ:RETA) in a research report sent to investors on Thursday, Analyst Price Targets reports. They currently have a $35.00 price target on the stock, down from their previous price target of $282.00. A number of other equities research analysts have also weighed in []

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Reata investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit you

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Reata Pharmaceuticals, Inc. (Reata or the Company) (NASDAQ: RETA) investors concerning the Companys possible violations of federal securities laws. On November 9, 2020, Reata announced that its Phase 3 CARDINAL study of bardoxolone in patients with chronic kidney disease by Alport syndrome met its primary and key secondary endpoints at the end of Year 2. Due to these results and a rec